Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsKeith E. Robision, Rosana Kapeller-Libermann, David White
Estimating the term…
The present invention relates to a newly identified human cyclic nucleotide phosphodiesterase belonging to the superfamily of mammalian phosphodiesterases. The invention also relates to polynucleotides encoding the phosphodiesterase. The invention further relates to methods using the phosphodiesterase polypeptides and polynucleotides as a target for diagnosis and treatment in phosphodiesterase-mediated or -related disorders. The invention further relates to drug-screening methods using the phosphodiesterase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the phosphodiesterase polypeptides and polynucleotides. The invention further relates to procedures for producing the phosphodiesterase polypeptides and polynucleotides.
An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of:
An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of:
An isolated nucleic acid molecule a polynucleotide having a nucleotide sequence selected from the group consisting of:
An isolated nucleic acid molecule having a nucleotide sequence having at least 70% sequence identity to the nucleotide sequence shown in SEQ ID NO:2 or SEQ ID NO:4 and retains cyclic nucleotide phosphodiesterase activity.
An isolated nucleic acid molecule having a nucleotide sequence having at least 80% sequence identity to the nucleotide sequence shown in SEQ TD NO:2 or SEQ ID NO:4 and retains cyclic nucleotide phosphodiesterase activity.
An isolated nucleic acid molecule having a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence shown in SEQ ID NO:2 or SEQ ID NO:4 and retains cyclic nucleotide phosphodiesterase activity.
Dependencies are inferred from the claim text.